Bristol-Myers Squibb and Emory University Announce Partnership to Advance Clinical Development of Investigational Compounds

First studies under the agreement to focus on clinical trial programs in oncology

Category:

Wednesday, June 20, 2012 8:30 am EDT

Dateline:

PRINCETON, N.J. & ATLANTA

Public Company Information:

NYSE:
BMY
"This partnership is aligned with Bristol-Myers Squibb’s strategy, which embraces the opportunity to selectively integrate the expertise of other organizations with our own to best meet the treatment needs of patients"

PRINCETON, N.J. & ATLANTA--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Emory University today announced the formation of a strategic partnership to conduct clinical trials involving Bristol-Myers Squibb’s investigational compounds.

Under the newly established Master Clinical Trial Agreement, investigators from Emory University and affiliated institutions will conduct Phase II, Phase III and pediatric clinical trials in the metropolitan Atlanta area to support the ongoing development of investigational medicines from across Bristol-Myers Squibb’s portfolio, particularly in oncology, metabolics, hepatitis C and immunoscience. This agreement builds on recent experiences between the two organizations in conducting clinical trials in organ transplantation and cancer.

In the first studies under the new agreement, researchers from the Winship Cancer Institute of Emory University will work with Bristol-Myers Squibb scientists on multiple clinical trial programs in oncology.

“This partnership is aligned with Bristol-Myers Squibb’s strategy, which embraces the opportunity to selectively integrate the expertise of other organizations with our own to best meet the treatment needs of patients,” said Brian Daniels, senior vice president, Global Development & Medical Affairs, Bristol-Myers Squibb. “Our expectation is that the shared commitment of providing innovative solutions for patients, the world-class talent at both organizations and the clinical trial expertise at Emory, will result in important advancements in the understanding of Bristol-Myers Squibb compounds and their potential for treating patients with devastating diseases, such as cancer.”

“Through this partnership, we are working to provide a framework to improve clinical trials efficiency and to enhance the development of academic and industry collaborations that solve health care problems,” says David S. Stephens, MD, vice president for research in Emory’s Woodruff Health Sciences Center and principal investigator of the Atlanta Clinical and Translational Science Institute (ACTSI). “Emory’s successful partnership with Bristol-Myers Squibb in developing drugs for organ transplantation is an excellent example of the benefits of these kinds of collaborations.”

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews. For more information on our clinical trials, please visit www. bms.com/clinical_trials.

About Emory University

Emory University is a leading educational and research institution that includes nine highly ranked colleges and professional schools and the state's most comprehensive health system. Emory's Woodruff Health Sciences Center is pioneering new ways to prevent and treat disease, driving technology-based economic development through translation of research into life-saving products, serving the local and global communities, and preparing the next generation to save and improve lives.

Contact:

Bristol-Myers Squibb
Media:
Jennifer Fron Mauer, 609-252-6579
jennifer.mauer@bms.com
or
Investors:
John Elicker, 609-252-4611
john.elicker@bms.com
or
Emory University
Media:
Holly Korschun, 404-727-3990
hkorsch@emory.edu

Search Press Releases

Reset



Subscribe to E-Mail Alerts

Business Wire NewsHQ℠